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ABSTRACT
The coronavirus disease-2019 (COVID-19) outbreak by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) or a novel coronavirus 
(2019-CoV) has prompted global health concerns. A pandemic resulted from the disease’s transmission through many routes. In this pandemic, the 
interaction between coronavirus and the host immune system, particularly the innate immune system, is becoming more prominent. Against viruses 
and pathogens, innate immunity serves as a first line of defense. Our understanding of pathogenesis will benefit from a better grasp of the mechanisms 
of immune evasion techniques. The origin, classification, structure, and method of transmission of SARS-CoV-2 were summarized in this paper. We 
have discussed the importance of important communications. In this review, we have discussed the function of important components of the innate 
immune system in COVID-19 infection, as well as how the virus evades innate immunity through multiple tactics and contributes to a wide range of 
clinical symptoms and outcomes.
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INTRODUCTION
The outbreak of new severe acute respiratory syndrome coronavirus-2 
(SARS-CoV-2) — the causal agent of Coronavirus disease 2019 
(COVID-19) – began in Wuhan, Hubei Province, China, in December  2019, 
and quickly spread throughout the country. COVID-19 was declared a 
global pandemic by the World Health Organization on March 11, 2020. 
Fever, dry cough, dyspnea, rhinorrhea, sneezing, sore throat, confusions, 
chills, muscle, chest pain, hemoptysis, pyrexia, acute respiratory distress, 
and diarrhea with nausea and vomiting are all possible symptoms, but 
they are less prevalent [1,59]. COVID-19 can cause mild MERS-CoV 
to severe SARS-CoV sickness, which can lead to hospitalization and 
intensive care unit admission and increased mortality among elder 
adults [58]. The International committee on taxonomy of viruses ICTV 
has named novel coronavirus (2019-Nov) as SARS-CoV-2 and the disease 
it causes is called COVID-19 [2]. SARS- CoV- 2 is the 7th identified human 
coronavirus and 3rd novel one to emerge in the past 20 years [60].
THE SARS-COV2: CLASSIFICATION AND ORIGIN
Coronaviruses are enclosed, single-stranded, and positive sense RNA 
viruses belonging to the Coronaviridae family of the Nidovirales 
order. Letovirinae and Orthocoronavirinae are two subfamilies of the 
Coronaviridae family. Alphavirus belongs to the Letovirinae family, 
while Alphacoronavirus, Betacoronavirus, Gamma Coronavirus, and 
Deltacoronavirus belong to the Orthocoronavirinae family (Fig. 1).
The human viruses HCoV-229E and HCoV-NL63 belong to the 
Alphacoronavirus genus. Mouse hepatitis virus (MHV) prototype, three 
human viruses (HCoV-oc43, SARS-HCoV, and HCoV-HKU1), and MERS-CoV 
are all members of the Betacoronavirus genus. Cetacean and bird viruses 
belong to the Gamma Coronavirus genus; the Deltacoronavirus belongs 
to the Deltacoron genus contains virus of pigs and birds [4-6].
ORIGIN
The novel coronavirus originated from the Hunan seafood market, 
Wuhan, China. SARS-CoV-2 genomes were sequenced and suggested 
that it might have also originated from bats but, still the zoonotic source 
for the spread of virus is not known. According to the phylogenetic tree, 
SARS-Cov-2 is closer to SARS-like bat coronaviruses, (CoVsZxC21and 
ZC45). Thus, this SARS-CoV-2 belongs to Betacoronavirus 
Subgenus sabecovirus [7]. Among the four genera of coronaviruses, 
alphacoronavirus and betacoronavirus can infect mammals while 
gamma coronaviruses and delta coronavirus tend to infect birds, six 
coronaviruses have been identified as human susceptible viruses, 
among which alpha coronaviruses: HCoV-229E and HCOV-NL63 and 
Betacoronavirus- HCoV-229E and HCov-NL63, and Betacoronavirus 
HCoV-HKU1 and HCoV-OC43 with low pathogenicity, cause mild 
respiratory symptoms similar to a common cold, respectively. The other 
two known Betacoornavirus, Sars-CoV and MERS-Cov lead to severe 
and potentially total respiratory tract infections [10].
TRANSMISSION
COVID-19 infection transmission was first classified as zoonotic 
(transmission of infection from animal to human). Later, it was suggested 
that human-to-human transmission was the primary mechanism 
of transmission for the present pandemic. Horizontal transmission 
through direct touch, aerosol transmission (viruses remain alive on at 
least 3 h in aerosol and 48–72 h on materials such as stainless steel and 
plastic surfaces), and droplet transmission are all examples of human-
to-human transfer (Fig. 2). Personal protective equipment can be used 
to prevent (b) fecal-oral transmission, (c) vertical transmission, and 
(d) nosocomial transmission of COVID-19 from patients to health care 
personnel vertical transmission and (d) nosocomial transmission of 
COVID-19 from patients to healthcare workers can be controlled using 
personal protective equipment. Fomites are the principal source of 
infectious particles through indirect contact [8]. The most harmful mode 
of COVID-19 transfer among HCWs is droplet mode transmission [9].
GENOTYPIC AND PHENOTYPIC CHARACTERISTICS OF SARS-COV2
Genotype
SARS-CoV2 is an enclosed, non-segmented, single-stranded, 
positive-sense RNA virus with a diameter of 60–120 nm [11,12], a 
size of roughly 29.9kb, and a nucleoprotein within a capsid. Matrix 
protein makes up the nucleoprotein. It features a helical symmetry 
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nucleocapsid and a lipid sheath produced from the previously 
infected host’s membrane. Glycoprotein projections in the shape of 
clubs can be found on the envelope (Fig. 4). Coronaviruses have the 
biggest genomes (ranging from 26.4 to 37.1 kb) of all known RNA 
viruses, with G and C content ranging from 32 to 43% [13]. With a 
genome size of 29,891 nucleotides and 9860 amino acids, SARS-CoV2 
contains a G and C of 38% [7].
The genome of coronavirus has a variable number of open reading 
frames (ORFs), ranging from 6 to 11. [10]. With seven ORFs, SARS-
CoV-2 RNA is 5’caped and 3’ polyadenylated [11]. ORF 1a and 1b 
make up two-thirds of the viral genome, encoding 16 non-structural 
proteins and translating two polyproteins, pp1a and pp1ab (NSP). 
The remaining ORFs code for structural proteins such as spike(s) 
protein, Envelope protein (E), Membrane protein (M), Nucleocapsid 
protein (N), and a few auxiliary proteins [10,11]. The coronavirus 
sgRNA is used to translate all structural and auxiliary proteins. 
ORF 10 and 11 of the 1/3rd genome, located near the 3›terminus, 
encode these proteins [13]. In addition, in some cases, the 
hemagglutinin esterase (HE) gene is located between ORF1b and 
ORF S [11,12,14,15].
PHENOTYPE
The membrane of the coronaviruses has 3 or 4 viral proteins.
Spike glycoprotein (S)
The coronavirus has spike-like protruding projections on its surface 
called large surface glycoproteins or spike (S) protein [16,17]. 
The S-protein plays a significant role in pathogenesis by binding 
to the host cell. It acts as a Type-I membrane glycoprotein with 
single channel peptide, responsible for host receptor binding, viral 
entry and with most variable sequencing in coronavirus genomes 
[17]. It consists of an ectodomain element, transmembrane moiety, 
and a short intracellular C fragment. Its molecular weight is about 
141178KDa and contains 1273 amino acids [16]. S1, S2, and S2’ are 
three subunits (Fig. 3). Through RBD, the S subunit is responsible 
for binding to the cell receptor (receptor binding domain). The 
SARS-CoV-2 S1 subunit enters the cell through the angiotensin-
converting enzyme 2 (ACE-2) host receptor. The lung, heart, ileum, 
kidney, and bladder all have higher levels of ACE 2. The S protein 
undergoes structural changes as it enters the endosomes of the host 
cells throughout this process. The S2 subunit functions as a fusion 
protein that aids in virion-cell membrane fusion. The s-protein is 
broken into S1 and S2 subunits by protease after binding to the S1/
S2 cleavage site. Another protease, such as transmembrane protease 
serine, can also cleave it.
Nucleocapsid protein (N)
The viral RNA is packaged inside the ribonucleocapsid by the 
nucleocapsid protein. The N-protein is the only protein found in 
nucleocapsids, and it is expressed in the host sample during infection’s 
early stages. The nucleocapsid N protein is a highly conserved portion 
of CoV that is 90% similar to SARS-CoV. It is a one-of-a-kind construct 
with a serine (SR)-rich linker region sandwiched between N- and 
C-terminal domains. It connects the viral DNA to a bead pattern on a 
thread [16,18].
Envelope protein (E)
CoV-2 E Protein has a molecular weight of 8–12 kDa and contains 75 
amino acids. It is a transmembrane protein containing an ectodomain 
at the N-terminus, a hydrophobic domain at the C-terminus, and 
an endodomain at the C-terminus that acts as an ion channel. This 
architecture encourages the virus to assemble and release itself [16]. 
SARS-CoV replication does not require it, but pathogenesis does 
involves with this protein [16,19,20].
Membrane protein (M)
M-protein is the most abundant protein in coronaviruses, and it is 
responsible for the virus’s unique shape. It is a 30kDa structure with 
three transmembrane domains, a short glycosylated N-terminal 
ectodomain, and a very big C-terminal endodomain. It is in charge of 
RNA packaging [14,16].
Viral Receptors
The primary indication of coronavirus host spectrum and tissue 
tropism is receptor attachment. Cell surface factors such as amine-
peptidase N for HCoV 229E, ACE-2 for SARS and SARS-CoV2, dipeptidyl 
peptidase 4 for MERS CoV, and O-acetylated sialic acid for HCoV-oC43 
serve as receptors. With the help of host proteases, the spike protein 
was activated. The endosomal cysteine protease cathepsins L and 
the trypsin-like serine protease trypsin-like serine protease trypsin-
like serine protease trypsin-like serine protease trypsin-like serine 
protease trypsin [21].
INNATE IMMUNITY
Innate immunity is the first line of defense (non-specific) against 
infections, with an antigen-independent defense mechanism and 
no immunologic memory. The innate immune system is critical for 
recognizing and eliminating contaminated cells during viral infections, 
as well as organizing an adaptive immune response. Anatomic, 
physiologic, endocyclic and phagocytic, and inflammatory barriers are 
among the four defensive barriers [25,26]. Macrophages, dendritic cells, 
mast cells, neutrophils, eosinophils, and natural killer cells play a role 
in innate immunity in both hematopoietic and non-hematopoietic cells. 
Its responsiveness is a feature of epithelial cells of the skin, respiratory 
tract epithelial cells, and IT cells, and the genitourinary tract.
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and into the systemic circulation, causing endothelial degradation 
and oxidative stress. In roughly 3–5% of all patients, an exaggerated 
immune response leads to a “cytokine storm” in the 2nd week, with 
IL-6 activating macrophages, monocytes, and T-cells. The importance 
of innate immunity in the outcome of COVID-199 infections cannot be 
overstated [32,61].
INNATE IMMUNE EVASION MECHANISMS
SARSCoV2 uses immune blunting, or delay, techniques to get beyond 
the host’s antiviral defenses, allowing for fast replication 33 or an 
intensification of the inflammatory response. 34 Virulence factors can 
mediate virus adhesion to epithelial cells via S protein, enhance virus 
dissemination through intercellular spaces through invasive enzymes, 
or provide resistance to host defense systems such IFN, NK cytotoxicity, 
and inflammatory response. SARSCoV2 has recently been discovered to 
share numerous structural and NS proteins with other coronaviruses, 
primarily SARSCoV (Figs. 5,6).
KEY COMPONENTS OF INNATE IMMUNITY IN COVID-19
Viral sensing PRRs
The most proximal event in the triggering and amplification of the 
innate immune response is the recognition of PAMPs and DAMPs [34]. 
The network of PRRs and accompanying signaling pathways is an 
important part of the innate immune system [35]. PRRs are germline-
encoded receptors located on all immune-responsive cells. CD14, a 
membrane and soluble protein (mCD14, sCD14) that acts as a PRR and 
enhances the activation of TLR2, TLR3, and TLR4 by bacterial, viral, and 
host-derived products, serves as a PRR. These proteins significantly 
boost the inflammatory response generated by PRR [34].
TLRS
TLRs are proteins that play a role in the innate immune system’s 
development and activation. PAMPs are recognized by a family of 11 
Transmembrane receptor proteins [3]. TLRs are membrane-spanning 
type I receptors containing extracellular leucine-rich repeats for ligand 
binding, a transmembrane domain, and a Toll-interleukin-1 receptor 
resistance (TIR) domain in the cytoplasmic tails to activate intracellular 
signaling [35]. These sensor proteins are involved in both “self” and 
“non-self” situations. It recognizes a conserved microbial domain that 
works as a ligand for elements such as lipids, lipoproteins, proteins, 
RNA, and DNA. These microbial domains are called the PAMP [36].
These receptors are classified based on whether they are expressed 
intracellularly or extracellularly. Intracellular receptors on the cell 
surface are engaged in the detection of bacterial products, while 
extracellular receptors expressed in endosomes are involved in nucleic 
acid detection. TLR3, TLR7, TLR8, and TLR9 are endosomes. TLR3 
recognizes double-stranded RNA, while TLR7 and TLR8 recognize 
single-stranded RNA. TLR9 recognizes hypomethylated CPG DNA [37].
It is abundant in dendritic cells, the placenta, and the pancreas [3]. TLR 
signaling is mediated by the TIR (Toll/IL-1 receptor) domain, which 
contains an adaptor molecule such as myeloid differentiation primary 
response gene 88 (MyD88), TIR-domain containing adaptor protein, or 
TIR-Domain containing adaptor inducing interferon Beta (TIR-Domain 
containing adaptor inducing interferon Beta) (TRIF) [38,39]. The TIR 
complex is involved in the generation of pro-inflammatory cytokines, 
type-I interferon, and the upregulation of costimulatory molecules 
during the inflammatory immune response [36].
Complement system
Inactive precursors of a group of proteins provide a protective effect 
against germs and viruses. There are three distinct pathways: Classic, 
alternative, and lectin, each of which activates different immune system 
components [3]. It acts as a catalyst for pro-inflammatory reactions [40]. 
It serves as a link between the innate and adaptive immune systems. It 
detects non-self-structures and activates zymogens through proteolytic 
cascades, leading to inflammation, opsonization, and cell lyrics [36]. 
During viral infections, the innate immune system is crucial for 
identifying and removing infected cells while also coordinating an 
adaptive immune response. To detect and defend rapidly against various 
microbes, mammalian hosts have evolved multiple pattern-recognition 
receptors (PRRs) including Toll-like receptors (TLRs), retinoic acid-
inducible gene I (RIG-I)-like receptors (RLRs), the nucleotide-binding 
oligomerization domain –like receptor family proteins (NLRs), and 
absent in melanoma 2 (AIM2). In response to specific pathogen-
associated molecular patterns (PAMPs) and danger-associated 
molecular patterns (DAMPs), some PRRs, particularly members of the 
NLR family and AIM2, have the ability to assemble a large multiprotein 
complex called the inflammasome [69]. Some PRRs, particularly those 
in the NLR family and AIM2, have the ability to form the inflammasome, 
a massive multiprotein complex [69] PAMPs are highly conserved 
pathogen products that should be detected by a collection of non-
clonal germline-encoded receptors with broad specificity [27,28]. 
The inflammasome causes membrane hole development and pro-
inflammatory cytokine processing when it is assembled, resulting 
in pyroptosis, a type of inflammatory cell death [69] The cell’s own 
endosomal and cytosolic PRRs identify pathogen nucleic acids. DAMPs 
from injured cells can also activate PPRs from damaged cells [29,30]. 
These RNA sensors start a signaling cascade in innate immunity 
against respiratory viruses when PAMPs are recognized by endosomal 
receptors (TLR 3,7,8) and cytosolic receptors (MDA5 and RIG-I). NFKB, 
IRF3, IRF7, and other transcription factors are activated as a result of 
this signaling pathway. Type I and type III interferons, as well as other 
pro-inflammatory cytokines and chemokines, are stimulated by these 
stimuli [31,27].
Interferons (IFNs) activate the IFN effector response through the JAK/SAT 
pathway, which results in the activation of Interferon-stimulated genes 
(ISGs) in infected and nearby cells. Type-III IFN has been discovered to 
be the first line of defense against respiratory viruses, and it does not 
cause significant inflammatory reactions [27]. During viral infection, 
innate immune signaling and inflammasome activation are well-known 
and important barriers. Excessive stimulation of the innate immune 
system, on the other hand, can lead to systemic inflammation and tissue 
damage, both of which are harmful to the host. A wide spectrum of viral 
illnesses causes systemic hyperinflammation [67].
INNATE IMMUNE RECOGNITION IN SARS-COV-2
When coronaviruses, such as SARS-CoV-2, come into touch with 
the respiratory mucosa, they try to enter the cells through host 
receptors such ACEs and envelope anchored S-glycoproteins [32]. The 
identification of S by membrane associated TLR2 through stimulation 
of the nuclear factor kB (NFkB) cascade in epithelial cells, monocytes, 
and macrophages can start the innate immune reaction signaling [22]. 
When a virus enters the cell, its ssRNA enters the endosome lumen 
and activates intracellular TLRs, primarily TLR7/8 [23]. Viruses 
subsequently reproduce rapidly within alveolar epithelial cells [24] and 
secondary structures with dsRNA domains are detected by a different 
form of cytosolic PRR, such as MDA5 or PKR, which, in turn, stimulate 
antiviral gene expression [25].
Through the IRF 3/7 and NF kB pathways, TLR and RLR stimulate 
transcription factors necessary for the generation of IFN I and 
pro-inflammatory cytokines. SARS-CoV2 can also enter through 
CD147; however, the mechanism and receptor binding motifs are 
unknown [33]. It begins to transcript its genomic RNA and generates 
structural and non-structural proteins after obtaining entry to the cell. 
It proliferates without being identified by the host’s innate immune 
response in the early days following infection by overpowering it. After 
a large number of cells have been infected, the symptoms begin with a 
high temperature and broad malaise [29].
Around 7 days following the onset of symptoms, the virus is either 
eliminated by the immune system, resulting in the patient’s recovery; 
or the virus moves into the lungs (particularly by type-2 pneumocytes) 
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their subsequent cytotoxic functions [33]. In peripheral blood of 
COVID-19 patients, the expression of KIRs and C16 in NK cells was 
significantly decreased, suggesting impaired maturation of NK cells or 
migration of circulating NK cells into the peripheral tissues of SARS-
CoV2 patients [50]. Cytokines like IL-12 secreted by Macrophages and 
dendritic cells promote NK cell proliferation, cytotoxicity, survival, and 
IFN-γ production. IFNλ mediated IL-12 production suggests that early 
production of IFN-γ and Nk-cell stimulation may act to limit SARS-CoV2 
infection [47].
In SARS-CoV-2 patients, the NK cells are functionally exhausted due to 
increased expressions of anNk inhibitory receptor called NKG2A and 
decreased expression of CD107a, IFn-γ, Il-2, and Granzyme B in NK 
cells [51]. There is also upregulated expression of the genes which 
encoding inhibitory receptors including TIM3 and LAG3 in NK cells 
from COVID-19 patients. While, Nk cells members and activity appears 
to be diminished in COVID-19 patients remains unelucidated. [47].
Dendritic cells
Dendritic cells are a diverse group of antigen-presenting cells that 
are widely distributed in the respiratory tract. These are two main 
categories of dendritic cells are plasmacytoid and conventional 
dendritic cells. In the early phase of infection almost all immune and 
non-immune cells produce IFN-I α/β in response to viral infectious 
plasmacytoid dendritic cells are considered as the main source of 
IFN-1 which is essential for the protection of the host; by promotes 
the removal of virus from the circulation by macrophage and also be 
the reason for individuals with non-severe COVID-19 [52]. SARS-CoV2 
infects Dcs among other cells which significantly contribute both innate 
and adaptive immunity. Dc has a peculiar characteristic of being able to 
enhance or suppress the immune system. Dc-specific molecular non-
integrin three adherent (DC-SIGN, CD 209) is a member of superfamily 
receptor of type C lectin that highly expressed on dc surface. This 
receptor allows interacting with both the pathogens and endothelial 
epithelial and myeloid cells. The binding requires mannose residues 
on the pathogen [53]. In acute SARS-CoV2 patients, the conventional 
DC’s (CD11c+) were significantly reduced than in the convalescent 
phase. The percentage of PDC (CD123) was also reduced although 
not significantly in both convalescent and acute patients. The ratio of 
CD11c+:CD123+ was higher in the acute phase, especially in severe 
cases. These findings suggest that SARS-CoV2 has cytopathic effects on 
dendritic cells [52]. Immature dendritic cells are turned as mature after 
antigen-capture which produces a wide variety of cytokines including 
IL-2, IL-1 β, IFN-α, β, γ, IL-4,10, and TNF α [52]. The capacity of Dcs 
to stimulate T cells depends on its maturation state, thus production 
infection of immature dendritic cells may delay the activation of T-cells 
Thus, the inability of dc to provide the switch from innate to adaptive 
immunity may be important for COVID-19 pathogenesis [52].
Interferon and cytokines
Interferon is signaling proteins involved in innate and adaptive immune 
responses, with an important role in the inhibition of viral replication 
through different effector proteins [3]. There are three types of 
IFN- type I (IFN- α, β), are largest IFN family includes IFN α (13 subtypes) 
encoded at chromosome 9,IFN β encoded at chromosome- 12; type II 
(IFN γ), and type III (IFN λ [3,36]. All three are involved in coronavirus 
infection [3]. Almost all types of cells are capable of producing IFN- α/β; 
pDCisa specialist in Type I IFN producing cells, particularly producing 
α, β, ω during the course of infection [36]. In the early stage of infection, 
type I has a predominant role, production is enhanced by viral RNAs 
through 2 cytosolic proteins: RIG-I and MDA5. This recognition of 
viral RNA leads to activation of IRF3 which determines the initiation 
of transcription of type I IFN [3,54]. SARS-CoV2 has several proteins 
including nsp1, nsp3, nsp16, ORF 3b, ORF6, and M and N proteins which 
act on the type I IFN pathway either by inhibiting the transcription or 
by acting on effector mechanisms. It was observed a peak in IFN α2 
production after 8-10 days of symptoms onset. Also observed in the ICU 
patients, the IFN-1 production was suppressed [3]. IFN- λ is present 
in lower airways in COVID-19 patient mediates antiproliferative 
Overactivation of complement may result in increased neutrophil and 
monocyte infiltration of the alveolar air sac as a result of excessive C3a 
and C5a production [42].
Collateral lung injury and aggravating variables for SARS-Cov-
associated ARDs result as a result of this. SARS-Cov2 is a respiratory 
disease, and the predominant antibody generated is IgA, which, unless 
based on an aggregated antibody, is not dependable for activation of 
the conventional complement system [36]. Instead, the virus might 
be from IgA complexes or SARS-Cov. S-N glycan (N-330)MBL binding 
stimulates the lectin complement pathway, which protects mucosal 
immunity from invading viruses [41]. C3a products of the complement 
cascade aggravate SARS-Cov related ARDs in SARS-Cov2, whereas C5a 
causes inflammatory cell activation and cytokine release in SARS-
Cov2. Degranulation of epithelial cells occurs as a result of this, and 
the number of epithelial cells increases vascular permeability, large 
number of inflammatory infiltrates, fluid and blood cells shift to alveoli, 
and lung pleura results in dyspnea and respiratory insufficiency [43].
Monocytes and macrophages
Mononuclear phagocyte systems present throughout the body. 
Monocyte-derived macrophages are the main generators of 
inflammation in COVID-19. These phagocytes have a wide range of 
plasma membranes and intracellular receptors [44]. In early infection, 
the occurrence of common symptoms due to the indirect result of 
epithelial cell necrosis by viral infection was mediated by ACE2 
and other co-receptors such as transmembrane protease serine2. 
(TMPRSS2) phagocytosis of virus or epithelial cell debris by lung 
macrophage canactivate inflammasome by P2Rx7 and release IL-1Beta, 
type-1IFN, IL-6, and TNF [44,62]. The inflammasome is a multiprotein 
complex, which is the part of the innate immune system responsible for 
the activation of inflammatory responses [3]. Activated Inflammasome, 
recruits pro-caspase-1(Proteolytic enzyme), which activates pro-
inflammatory cytokines such as pro-IL-1 B and pro-IL-18 by cleaving 
it. This leads to programmed cell death called pyroptosis [3]. IL-18 
stimulates the production of IFN-γ, which determines the development 
of TH1 results in adaptive immunity development [45]. IL-1 released 
by macrophages through inflammasome contributes to cytokine storms 
responsible for a most aggressive form of COVID-19 [3].
Neutrophils
In COVID-19, the CBC profile was found to observe an increase in 
Neutrophil with lymphopenia. These cells may contribute to the healing 
process through virus clearance and production of growth factors for 
healing and reepithelialization of damaged regions of the lungs [3]. In 
SARS-Cov2 respiratory epithelium, infections result in cell secretions of 
multiple cytokines, chemokines, and DAMPs which facilitates the PMN 
recruitment to the site of infection [46]. Viral infection can induce the 
release of neutrophil extracellular traps (NETs) by neutrophils NETs 
are known to immunize and degrade bacteria, fungi, and viruses [46]. 
NETs released neutrophil contributes to organ damage and mortality 
in COVID-19 patients [47]. Net comprises extracellular DNA fibers, 
histones, microbiological proteins proteases such as neutrophil 
elastase, and oxidant enzymes such as myeloperoxidase, which are 
released by neutrophils at the time of infection [47]. This process is 
called NETosis and plays a role in controlling pathogens but also has 
detrimental effects on cardiovascular and pulmonary disease. Mitosis 
in COVID-19 infection has a role in vascular complications, where 
thrombotic disease can drive organ damage [48]. High levels of IL-6 
observed in COVID-19 patients induce NETs. Additional triggers of 
NETosis include viral-damaged epithelial cells, activated endothelial 
cells, activated platelets, and inflammatory cytokines like IL_1β [47].
NK CELLS
Essential in control of viral infections and functional impairment of NK 
cells correlates with the persistence of SARS-Cov2. In COVID-19 patients, 
Nk Cells were found to be reduced [33]. The plasma membrane of 
NK cells along with CD16 it also has killer immunoglobulin-like 
receptors (KIRs) which have crucial roles in NK cells, licensing, and 
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effects during repair of the lung epithelium, this effect occurs through 
p53 induction [47]. Type-I IFNs bind to the transmembrane receptor, 
IFNAR, composed of IFNAr1 and IFNAR2, these lead to activation of the 
intracellular signaling pathway JAK/STAT which initiates transcription 
of ISGS [49,55].
Cytokines
COVID-19 patients experience a “cytokine storm” that drives much 
of the pathophysiology of the disease. In SARS-CoV-2 patients, there 
will be an increase in both pro-inflammatory and anti-inflammatory 
circulating cytokines [56,47]. The pro-inflammatory cytokines 
including G-CSF, TNF α, MCP 1, IL-10, IL-2, IL-7, and IL-1 β were 
Fig. 1: Classification of SARS-CoV-2
Fig. 2: Modes of transmission of SARS-CoV-2
Fig. 3: Schematic representation of SARS-CoV-2 structure
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Fig. 5: (a) RLR family of innate immune receptors induce Type I 
interferon. The family of RIG-I Like Receptors (RLRs) contains 
three cytosolic RNA helicases that recognize non-self RNA species 
resulting from viral replication [93]. The two signaling sensors 
within the RLR family are RIG-I and melanoma differentiation 
associated factor 5 (MDA5). The third RLR, laboratory of genetics 
and physiology 2 (LGP2, not shown), facilitates recognition of viral 
PAMPs by RIG-I and MDA5, but is dispensable for their signaling [94]. 
RIG-I recognizes primarily 50 ppp-RNA molecules with secondary 
motifs of dsRNA or ssRNA of short length [95,96]. MDA5 recognizes 
longer dsRNA motifs than RIG-I [97]. Following binding of viral 
RNAs, RIG-I and MDA5 interact with the mitochondrial membrane 
bound adaptor molecule MAVS (mitochondrial antiviral signaling 
protein, also referred to as IPS-1, VISA, or CARDIF) to transduce 
the signal through complexes of kinases: the IKKe/TBK1 complex 
and the IKKa/IKKb/IKKg complex. The IKKe/TBK1 kinases 
phosphorylate the transcription factors IRF3 and IRF7, which 
then form homodimers or heterodimers. On dimerization, the 
transcription factors enter the nucleus to initiate transcription of 
Type I IFNs (IFN-a and IFN-(b). While IRF3 is nearly ubiquitously 
expressed in cells, IRF7 is an ISG typically expressed at low levels, 
so it is thought that IRF3 mediates transcription of the majority of 
early IFN expression
Fig. 6: Pathogen associated molecular pattern sensing by TLRs. 
(a) In the endosomal compartment, TLRs recognize viral nucleic 
acid PAMPs: TLR3 recognizes dsRNAs, TLR7/8 recognizes 
ssRNAs, and TLR9 recognizes CpG DNA motifs. (b) On the 
surface of cells, TLR2 and TLR4 are known to recognize viral 
glycoproteins [47,99]. TLR2/6 heterodimers help to activate the 
innate immune response to RSV, though the viral PAMP recognized 
has not been determined [100]. TLR1/2 heterodimers have been 
shown to recognize viral glycoproteins, though their potential 
role in respiratory virus infection has not been determined [99]. 
While there are many TLRs that recognize viral PAMPs, they signal 
through common adaptor molecules, including MyD88, MAL, 
TRAM, and TRIF. The TLR adaptor molecules signal through the 
IKKe/TBK1 complex and the IKKa/IKKb/IKKg complex similarly 
to RLRs, but can also recruit an IRAK-1/IRAK4/TRAF6 complex 
capable of activating the transcription factors IRF3, IRF7, and 
NF-kB. Activation of these transcription factors leads to the 
transcription of Type I IFNs and pro-inflammatory cytokines. Due 
to the considerable crosstalk between TLR and RLR signaling, 
it is difficult to discriminate between transcriptional products 
generated by the two sensor families, but it is likely that both play 
an important role in the innate immune response to SARS-CoV 
infection [68]
Fig. 4: Representation of 5′ capped mRNA has a leader sequence (LS), poly-A tail at 3′ end, and 5′ and 3′ UTR. It consists of ORF1a, ORF1b, 
Spike (S), ORF3a, Envelope (E), Membrane (M), ORF6, ORF7a, ORF7b, ORF8, Nucleocapsid (N), and ORF10 Rrp
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elevated. Importantly in ICU patients have a significantly higher level of 
GCSF, IP-10, MCP, and TNF- α; anti-inflammatory cytokines like IL-10  4 
were also increased [47,57], IL-6 is a major driver in pathology and 
found to be in the highest level in non-survivors and critical patients 
(Figs. 5,6). The other pathways in severe COVID-19 where SARS CoV 
trigger the production of oxidized phospholipids that leads to IL-6 
production by TLR4 through NFkB and MAPK signaling pathways 
N-Proteins of SARS-CoV-2 also induce IL-6 expressions [47]. Such a pro-
inflammatory signature indicates a systemic exaggerated, pathological 
Innate Immunity response [27].
RIG-I like receptor signaling
The RIG-I Like Receptors are cytoplasmic sensors that detect viral 
RNA PAMPs in a wide range of cell types (Fig. 2). The RLRs RIG-I 
and MDA5 are ISGs that are transcribed during SARS-CoV infection 
in vitro [23]. MHV, another coronavirus, is recognized by MDA5 in 
brain macrophages and microglial cells, and by RIG-I and MDA5 in 
oligodendrocyte cells [44,45]. Although it is not known whether 
SARS-CoV is recognized by RLRs, MHV and SARS-CoV are likely to have 
similar replication intermediates (putative RLR ligands), so it is likely 
that SARS-CoV could be detected by the same sensors. RLR signaling 
leads to the activation of several transcription factors: IRF3, IRF7, 
and NF-kB. IRF3and IRF7 initiate transcription of Type I IFNs (IFN-a 
and IFN-b), important for an antiviral response. NF-kB mediated 
transcription of pro-inflammatory cytokines has been linked to 
the pathogenesis of ARDS [46]. In vitro SARS-CoVinfections have 
demonstrated that the expression of NF-kB generated transcripts, 
such as IL-6 and IL-8, happens as early as 12 h post infection, while 
IRF3/IRF7 transcription of Type I IFNs is delayed until 48 h post 
infection [23]. Similarly, in the macaque model of age-dependent 
SARS-CoV pathogenesis NFkB induced genes is more highly 
expressed in aged macaques that have significantly increased lung 
injury compared to young adult macaques where higher expression 
of IFNs was observed [40]. While the correlation of severe SARS-CoV 
disease with different transcriptional regimes is promising, the key 
to finding determinants of increased SARS-CoV pathogenesis may 
be how innate immune sensing mechanisms initiate transcription at 
critical junctures during infection and which types of innate immune 
sensing are protective.
SARS-COV2’S STRATEGIES TO EVADE INNATE IMMUNITY
Coronavirus has several strategies to evade innate immunity, including 
the evolution of low genomic CpG, RNA shielding, masking of potential 
key antigenic epitopes, and also inhibition of steps in IFN type I/III 
pathways [63].
Evading zinc-finger antiviral protein (ZAP) action
In mammals, the ZAP is also known as ZC3HAV1 and in humans, GAAP. 
It is an important part of the mammalian interferon-mediated immune 
response that binds to CpG dinucleotides in viral RNA genomes. It 
prevents viral replication and aids in the breakdown of viral genomes. 
SARS-Cov2 has the most severe cytosine-phosphate-guanosine (CpG) 
deficit of any beta coronavirus; hence, it is immune to ZAP [64].
RNA capping
The process of 5’ end capping protects mRNA utilized by the host and 
viruses by limiting degradation and, more crucially, blocking recognition 
by cytosolic PRRs. SARS-CoV-2 has its own copping machinery, which 
consists of nsp10, nsp13, and the enzyme nsp16, which results in RNA 
caps that are indistinguishable from cellular mRNA caps. This helps to 
avoid detection by MDA5, IFIT, a protein that degrades target RNA [65].
PRR evasion by limiting its activity
Coronavirus works to evade the immune system by reducing PRR 
activity. The virus replicates in a double-membrane structure from 
the endoplasmic reticulum, which lacks PRRs, protecting it from both 
cytosolic and endosomal PRRs. The PRR signaling pathway is likewise 
suppressed. RIG is degraded by N-proteins, and coronaviruses decrease 
TLR signaling and cause TLR-associated signaling dysregulation [47].
TLR
In severe COVID 19 individuals, the SARS-CoV2 prevent successful 
immune response by inhibiting TRAF-3 and 6, has an essential role in 
inducing IRF-3/7 in response to activated TLR-7 [37].
To protect viral RNA and protein epitopes
SARS-Cov2 uses glycans and other post-translational modifications to mask 
immunogenic viral proteins epitopes during syncytia formation, allowing 
for the protection of viral RNAs, a protein generated during replication, in 
the use of replicase-transcriptase complex or replication organelle formed 
of double-membrane: Coronavirus uses glycans and other post-translational 
modifications to mask immunogenic viral proteins [63].
Inhibition in IFN production
SARS-Cov2 also developed techniques to block phases in the 
type I/III IFN production pathway. IFN antagonism has been attributed 
to a number of structural, non-structural, and accessory POTUS 
that interfere with the STING-TRAF3-TBK1 complex, preventing 
STING/TBK/IIKKE-induced type-I IFN production; signal transducer, 
and transcription activation, IRF3 NFkB signaling, as well as interfering 
with the action of ISG products such as IFTs [63]. Tetherin, also known 
as Bone Marrow Antigen 2), is inhibited by ORF7a [66].
CONCLUSION
The innate immune system’s detection of distinct CoVs, as well as the 
inflammatory cell death pathways activated in response to diverse CoV 
infections, have been highlighted. For host defense, optimal cell death 
and inflammatory cytokine release are critical. However, in CoV-infected 
patients, excessive host inflammatory responses and cell death can result in 
cytokine storms and/or tissue damage, increasing morbidity and mortality. 
To decrease excessive inflammation while maintaining antiviral effects, 
CoV-induced innate immunity and cell death must be delicately managed.
When developing evidence-based treatment methods, it will be critical 
to mechanistically characterize the innate immune response to distinct 
CoV infections and evaluate the clinical efficacy of targeting innate 
immune pathways. SARS-CoV-2 infection, for example, suppresses 
type I and type III IFN production while increasing the expression of 
chemokines and pro-inflammatory cytokines [10], both of which are 
linked to a poor prognosis. Reduced innate antiviral defenses, as well 
as increased inflammatory cytokine production, could be some of the 
driving factors in CoV-mediated illnesses.
The SARS-CoV-2 epidemic is still spreading over the world, and we 
urgently need efficient treatments and vaccinations to tackle COVID-19. 
Given the urgency of the global health situation, researchers are looking 
into repurposing existing therapeutic agents that have been approved 
or are in development/testing for other infections, such as malaria 
(Plasmodium sp.), HIV, or other CoVs, or for blocking the inflammasome 
(e.g., colchicine) or the pro-inflammatory cytokines IL-1 and IL-6. The 
results of these treatments have been varied.
For example, despite having several comorbidities, all five patients in a 
recent pilot study of COVID-19 who were previously receiving colchicine 
treatment presented with mild/moderate illness and survived. However, 
because this was a tiny observational study, definitive results could not be 
drawn. Despite positive early evidence from retrospective and single-center 
investigations utilizing IL-6–antibody blockade therapy, current research 
have revealed that blocking IL-6 is linked to an increase in secondary 
infections, and big phase III trials using these inhibitors have yielded mixed 
outcomes [68]. A better knowledge of the mechanisms through which the 
innate immune system recognizes and responds to foreign substances will 
be key aspects for the development of putative therapeutic strategies.
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